Physician

Joseph Allen Moore, MD

According to 2025 Medicare claims, Joseph Moore, MD (NPI: 1750777959) practices hematology/oncology in the Wichita, KS market, with the plurality of this provider's patient population coming from Sedgwick, KS. This provider's primary affiliated billing organization is CANCER CENTER OF KANSAS, P.A. (NPI: 1841251394; TIN: 481181579) and primary practice location at 67208-3006. Moore is affiliated with the Aledade 38 KS CHC MSSP Enhanced (ACO ID: A4546) and Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Moore's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,466 traditional Medicare patients, billed 510,401 HCPCS/CPT codes, and received $9,243,537 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,692 prescription claims across 408 beneficiaries totaling $4,723,001 in drug costs, led by Cabometyx (Cabozantinib S-Malate). DME data shows 68 claims. Open Payments data shows 242 records totaling $11,869. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $20,212 to $4,723,001. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	247	50,226	$683,317
2022	656	216,797	$2,763,375
2023	1,071	348,975	$5,291,998
2024	1,466	510,401	$9,243,537

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	18	$20,212
2020	12	52	$125,996
2021	61	178	$70,820
2022	198	1,139	$1,452,483
2023	282	1,790	$2,941,961
2024	408	2,692	$4,723,001

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	12	$782
2023	N/R	68	$16,666
2024	11	68	$3,270

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	382	1,128	$89
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	447	985	$12
96372	Injection of drug or substance under skin or into muscle	359	932	$10
85027	Complete blood cell count (red cells, white blood cell, platelets), automated test	334	1,781	$6
85007	Microscopic examination for white blood cells with manual cell count	334	1,778	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Cabometyx	Cabozantinib S-Malate	28	840	$700,142
Lenalidomide	Lenalidomide	54	1,274	$627,611
Revlimid	Lenalidomide	28	735	$455,014
Jakafi	Ruxolitinib Phosphate	25	750	$426,396
Pomalyst	Pomalidomide	12	336	$319,396

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	16	$1,175
J8521	Capecitabine, oral, 500 mg	N	N/R	18	$855
J8700	Temozolomide, oral, 5 mg	N	N/R	11	$807
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	11	23	$433

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	242	$11,869	BeiGene USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Joseph Allen Moore, MD?

Tedicare shows public-source Medicare data for Joseph Allen Moore, MD (NPI 1750777959), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Joseph Allen Moore, MD have ACO affiliation data?

Joseph Allen Moore, MD is shown with ACO affiliation data for Aledade 38 KS CHC MSSP Enhanced (MSSP, ACO ID A4546) and Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Joseph Allen Moore, MD?

Joseph Allen Moore, MD is linked to CANCER CENTER OF KANSAS, P.A. (billing NPI 1841251394) in the available physician profile data.

Does Joseph Allen Moore, MD have Open Payments data?

Joseph Allen Moore, MD has 242 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.